{"transactions":[{"id":1376134,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Common Stock","published_at":"2024-11-05T22:00:15.000Z","date":"2024-09-23","kind":"grant","planned":false,"acquired":true,"shares":90909,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The original Form 4, filed on September 24, 2024, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the amount of restricted shares granted."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":660909,"source":{"system":"sec-edgar","filing":"0001415889-24-026168","document":"form4a-11052024_051110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588924026168/form4a-11052024_051110.xml","form_type":"4/A","original_submission_date":"2024-09-24"}},{"id":1400489,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Common Stock","published_at":"2024-09-24T21:00:09.000Z","date":"2024-09-23","kind":"grant","planned":false,"acquired":true,"shares":99010,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":669010,"source":{"system":"sec-edgar","filing":"0001415889-24-023907","document":"form4-09242024_050905.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588924023907/form4-09242024_050905.xml","form_type":"4"}},{"id":1804393,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Common Stock","published_at":"2023-08-17T20:30:42.000Z","date":"2023-08-15","kind":"grant","planned":false,"acquired":true,"shares":201903,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":570000,"source":{"system":"sec-edgar","filing":"0001104659-23-093070","document":"tm2324046-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465923093070/tm2324046-3_4seq1.xml","form_type":"4"}},{"id":2162707,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:03:02.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 80,000 shares of common stock at an exercise price equal to $2.00 per share that expire on September 22, 2029."}],"balance_after":350000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001104659-22-098950","document":"tm2225460-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098950/tm2225460-7_4seq1.xml","form_type":"4"}},{"id":2369934,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Common Stock","published_at":"2022-02-28T22:02:20.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":121951,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":368097,"source":{"system":"sec-edgar","filing":"0001104659-22-028159","document":"tm227910-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922028159/tm227910-2_4seq1.xml","form_type":"4"}},{"id":3057693,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Common Stock","published_at":"2020-08-14T21:01:49.000Z","date":"2020-08-11","kind":"grant","acquired":true,"shares":246146,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The original Form 4, filed on August 13, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the vesting schedule of the restricted shares."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the \"Plan\"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the \"Plan\"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":246146,"source":{"system":"sec-edgar","filing":"0001104659-20-095626","document":"tm2027654-2_4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920095626/tm2027654-2_4a.xml","form_type":"4/A","original_submission_date":"2020-08-13"}},{"id":3059114,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Common Stock","published_at":"2020-08-13T21:03:11.000Z","date":"2020-08-11","kind":"grant","acquired":true,"shares":246146,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the \"Plan\"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":246146,"source":{"system":"sec-edgar","filing":"0001104659-20-094755","document":"tm2027548d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920094755/tm2027548d3_4.xml","form_type":"4"}},{"id":3407273,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2019-09-24T21:01:16.000Z","date":"2019-09-22","kind":"grant","acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."}],"balance_after":800000,"derivative":{"exercise_price":0.2,"expiration_date":"2029-09-22","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001144204-19-045806","document":"tv530009_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420419045806/tv530009_4.xml","form_type":"4"}},{"id":4156705,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (right to buy)","published_at":"2017-11-20T21:26:51.000Z","date":"2017-11-20","kind":"grant","acquired":true,"shares":93686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option shall vest and become exercisable as to 25% of the underlying shares on each of the first, second, third and fourth anniversary of the date of grant, until fully vested and exercisable on the fourth anniversary of the date of grant, provided Reporting Person remains employed by Brainstorm Cell Therapeutics Ltd. from the date of grant through each applicable vesting date."}],"balance_after":93686,"derivative":{"exercise_price":4.3,"exercise_date":"2018-11-20","expiration_date":"2027-11-20","underlying":"Common Stock","underlying_shares":93686},"source":{"system":"sec-edgar","filing":"0001144204-17-060168","document":"tv478601_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000114420417060168/tv478601_4.xml","form_type":"4"}},{"id":4156704,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2017-11-20T21:26:51.000Z","date":"2017-11-20","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired are shares of restricted stock awarded on November 20, 2017 under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock vest as to 100% of the award on April 1, 2018, provided that the Reporting Person remains continuously employed by Brainstorm Cell Therapeutics Ltd. from the date of grant through the vesting date."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001144204-17-060168","document":"tv478601_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000114420417060168/tv478601_4.xml","form_type":"4"}}]}